跳至主要内容
临床试验/NCT05348629
NCT05348629Unknown不适用

Efficacy and Safety of Covid-19 Vaccine in Cardiac Patients

Mina sobhi said fam2 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2022年6月1日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
50
试验地点
2
主要终点
Myocardial infarction

研究概览

简要总结

Efficacy and safety of covid-19 vaccine in Cardiac patients

详细描述

investigate the efficacy and safety of covid-19 vaccine in cardiac patients and its possible assocciated morbidity

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects diagnosed as STEMI undergo PPCI as (Fourth universal definition of myocardial infarction (2018) Kristian Thygesen) 10
  • with age range from 18 to 80 years after 1 month of STEMI .

排除标准

  • Patients with previous covid infection confirmed by swap or CT chest or ICU addmision.
  • Patients with previous covid infection confirmed by qualitative antibdy test .
  • Patients with history of anaphylaxis to any component of the vaccine should not take it .
  • patients with febrile illness or acute , ongoing infection .
  • immunosuppressive diseases .

结局指标

主要结局

Myocardial infarction

时间窗: one year

Myocardial infarction

stent thrombosis

时间窗: one year

stent thrombosis

all cause mortality

时间窗: one year

all cause mortality

次要结局

  • heart failure hospitalization(one year)
  • anaphylaxis required hospitalization(one year)
  • Cardiovascular death. Cardiovascular death. Cardiovascular death.Cardiovascular death. cardiovascular death(one year)
  • infection by covid-19(one year)

研究者

发起方
Mina sobhi said fam
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Mina sobhi said fam

resident doctor

Assiut University

研究点 (2)

Loading locations...

相似试验